Novartis India Ltd Share Price – BSE

Pharmaceuticals, Small Cap

Net profit of Novartis India declined 13.82% to Rs 25.25 crore in the quarter ended March 2026 as against Rs 29.30 crore during the previous quarter ended March 2025. Sales rose 7.95% to Rs 90.55 crore in the quarter ended March 2026 as against Rs 83.88 crore during the previous quarter ended March 2025.

For the full year,net profit declined 7.65% to Rs 93.18 crore in the year ended March 2026 as against Rs 100.90 crore during the previous year ended March 2025. Sales declined 0.54% to Rs 354.33 crore in the year ended March 2026 as against Rs 356.27 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Novartis India will hold a meeting of the Board of Directors of the Company on 12 May 2026.

Novartis India announced that Sandra Martyres (DIN: 00798406), Independent Director, shall be completing her second and final term as an Independent Director of the Company on 18 April 2026. Accordingly, she ceases to be the Director of the Company w.e.f. close of business hours of 18 April 2026.

Powered by Capital Market - Live News

The board of Novartis India at its meeting held on 27 March 2026 has approved the appointment of Gowree Gokhale (DIN: 09351661) as an Additional Director (designated as Non-Executive and Independent Director) on the Board of the Company for a period of 5 (five) consecutive years with effect from 01 April 2026 up to 31 March 2031, subject to approval of the Members of the Company.

Powered by Capital Market - Live News